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Immunoglobulin Light Chain Amyloidosis Do Not
Impact Stem Cell Mobilization or Engraftment
Andrew J. Cowan,1 David C. Seldin,1,2 Martha Skinner,1 Karen Quillen,2,3 Gheorghe Doros,1,4
Josenia Tan,3 Carl O’Hara,1,3 Kathleen T. Finn,1,2 Vaishali Sanchorawala1,2Amyloid deposits are often found in the bone marrow in patients with Immunoglobulin light chain (AL)
amyloidosis. We sought to determine whether this affects stem cell collection or engraftment after high-
dose melphalan and autologous stem cell transplantation (HDM-SCT). We reviewed data on 361 patients
with AL amyloidosis who had Congo red staining of pretreatment bone marrow biopsy specimens and un-
derwent HDM-SCT between July 1994 and December 2011. We analyzed data on stem cell yield, days of
stem cell collection, and days to neutrophil and platelet engraftment posttransplantation. Bone marrow am-
yloid deposits were found in 65% of patients (n5 233). There were no significant differences in median num-
ber of stem cells collected and days to neutrophil or platelet engraftment between patients with bone
marrow amyloid deposits and those without these deposits. Thus, our data indicate that although amyloid
involvement of the bonemarrow is common, it does not negatively affect stem cell mobilization or neutrophil
and platelet engraftment after HDM-SCT.
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High-dose melphalan (HDM) and autologous
stem cell transplantation (SCT) is an important treat-
ment modality for selected patients with immunoglob-
ulin light chain (AL) amyloidosis [1]; however,
typically fewer than one-half of newly diagnosed pa-
tients are eligible for this treatment [2]. SCT is used
successfully in treatment of multiple hematologic dis-
orders and some solid tumors. A rare complication is1Amyloid Treatment and Research Program, Boston Uni-
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oi.org/10.1016/j.bbmt.2012.07.016primary graft failure, which was reported in 4.7% of
a recent series of 300 patients undergoing SCT [3].
Variables associated with favorable engraftment
kinetics include CD341 stem cell dose, as esta-
blished by multiple transplantation studies [4-6]. Pre-
vious studies have also demonstrated that exten-
sive antecedent exposure to alkylating agents nega-
tively impacts platelet engraftment [6,7]. A study of
SCT in patients with AL amyloidosis identified
CD341 stem cell dose, female sex, and previous alky-
lator therapy as important variables affecting stem
cell engraftment [8].
Amyloid deposition in the bone marrow (BM) is
common in patients with AL amyloidosis, documented
in 60% of biopsy specimens in a series of 100 patients
[9]. Two distinct histological patterns of BM amyloid
deposition have been identified: vascular and intersti-
tial. Here we report on the impact of amyloid deposits
in the BM on stem cell mobilization and engraftment
kinetics in patients with AL amyloidosis who under-
went HDM-SCT.METHODS
We conducted a retrospective review of data re-
corded between July 1994 and December 2011 in1935
Table 1. Patient Characteristics
BM Amyloid
Deposits
(n 5 233)
Interstitial BM
Amyloid
(n 5 83)
No BM
Amyloid
(n 5 128)
P Value, Amyloid
versus
No Amyloid
P Value, Interstitial
Amyloid versus
No Amyloid
Age, years, median (range) 56 (28-80) 56 (28-71) 57 (35-79) .88 .07
Female sex, n (%) 91 (39) 34 (41) 51 (40) .88 .87
Clonality, n (%)
Kappa 51 (22) 25 (30) 20 (16) .15 .01
Lambda 182 (78) 58 (70) 108 (84) .15 .01
Organ involvement, n (%)
Renal 221 (95) 77 (93) 95 (74) <.001 <.001
Cardiac 109 (47) 34 (41) 59 (46) .90 .46
Hepatic 77 (33) 49 (59) 20 (16) <.001 <.001
Soft tissue 50 (21) 16 (19) 39 (30) .06 .07
Gastrointestinal 53 (23) 20 (24) 18 (14) .05 .06
Autonomic nervous system 68 (29) 21 (25) 21 (16) .01 .11
Peripheral nervous system 25 (11) 5 (6) 13 (10) .87 .29
Pulmonary 14 (6) 7 (8) 6 (5) .60 .27
More than 2 organs involved 116 (50) 45 (54) 41 (32) .001 .001
Baseline laboratory values
Serum creatinine, mg/dL 1.1 (0.4-14.8) 1.2 (0.5-11.7) 0.9 (0.4-13.3) .80 .66
24-hour urine protein, mg 5875 (<60-58,212) 5797 (<60-27,456) 3629 (<60-20,493) .09 .004
Bone marrow plasma cells, % 5 (5-25) 5 (5-25) 10 (<5-30) .06 .28
Previous treatment, n (%)
Alkylator-based treatments 54 (23) 21 (25) 21 (16) .06 .049
Immunomodulatory drug-based treatments 3 (1) 0 (0) 6 (5) .06 .049
igure 1. Extensive interstitial amyloid deposition in a patient with
L amyloidosis, with almost total replacement of the BM. Amyloid is
ighlighted by periodic acid-Schiff and Congo red stains.
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Program database. Patients with AL amyloidosis who
underwent HDM-SCT at this institution and had
documented Congo red staining performed on the
initial BM biopsy specimen were included in our anal-
ysis. Patients who initiated stem cell mobilization but
did not proceed to HDM owing to either death or
complications were excluded. Patients who completed
a course of HDM but died before platelet or neutro-
phil engraftment were included in the overall analysis
but were excluded from the analysis of engraftment
kinetics.
Data were collected on baseline demographics,
laboratory test results, organ involvement, and previ-
ous treatment. Baseline data were collected on quanti-
tative serum free light chain assay and BM plasma cell
percentage, and the difference in involved free light
chain and uninvolved free light chain (dFLC) was cal-
culated. Data on stem cell collection yield, number of
days of collection, and days to neutrophil and platelet
engraftment posttransplantation were collected and
analyzed.
Amyloid deposits in BM biopsy specimens stained
with Congo red were graded as 0 (absent), 11 (vascu-
lar only), 21 (limited interstitial deposits, \2/high-
power field), or 31 (extensive interstitial deposits,
.2/high-power field). Neutrophil engraftment was
defined as an absolute neutrophil count of .500
cells/mL for 2 consecutive days, and platelet engraft-
ment was defined as a platelet count .20,000/mL
without platelet transfusion during the previous 48
hours.Descriptive statistics were used to summarize pa-
tient characteristics. c2 tests were used for comparing
proportions, and t tests were used for comparing
means. A P value#.05 was considered statistically sig-
nificant. All statistical analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC).RESULTS AND DISCUSSION
Patient Characteristics
A total of 361 patients with AL amyloidosis and
documented Congo red staining of initial BM biopsy
specimens underwent HDM-SCT (Table 1). TheF
A
h
Table 2. Stem Cell Collection and Engraftment Data
BM Amyloid
Deposits
(n 5 233)
Interstitial BM
Amyloid
(n 5 83)
No BM Amyloid
Deposits
(n 5 128)
P Value,
Amyloid versus
No Amyloid
P Value, Interstitial
Amyloid versus
No Amyloid
CD34+ cells collected, 106, median (range) 6.8 (0.2-31.4) 7.23 (0.6-24.1) 6.9 (0.28-20.4) .988 .79
Number of collections, mean (range) 2 (0.5-5) 2 (1-4) 2 (1-4) .444 .132
Time to neutrophil engraftment, days, median (range) 10 (5-16) 10 (5-16) 10 (8-17) .691 .213
Time to platelet engraftment, days, median (range) 13 (7-93) 13 (7-32) 12 (8-46) .177 .79
Biol Blood Marrow Transplant 18:1935-1944, 2012 1937Amyloid Deposits in Bone Marrow in AL Amyloidosismajority of patients (233; 65%) had evidence of BM
amyloid deposition; 150 of these 233 patients (64%)
had vascular amyloid deposition only (11), 27 had
limited interstitial amyloid deposition (12%), and
56 (24%) had extensive interstitial amyloid deposition
(Figure 1). All together, 83 patients (36%) had intersti-
tial amyloid deposition, and 128 patients (35%) had no
amyloid deposition.
Clonality was more frequently lambda than kappa
in all groups. Kappa predominance was detected in 25
patients (30%) with interstitial amyloid deposition
(30%), compared with 20 patients without BM amy-
loid deposition (16%) (P 5 .01).
Organ involvement differed among the study
groups. Coexistent renal involvement was present in
221 patients (95%) with BM amyloid deposition, com-
pared with 95 patients (74%) without BM amyloid de-
position (P \ .001). Multiorgan involvement (more
than 2 organs) was found in 116 patients (50%) with
amyloid BMdeposition and in 54% of patients with in-
terstitial amyloid (54%), compared with 41 (32%) of
those without BM amyloid deposition (P 5 .001 for
both comparisons).
Fifty-four patients (23%) with BM amyloid de-
position had received previous treatment before
HDM-SCT, compared with 21 patients (16%) with-
out BM amyloid deposition, an insignificant difference
(P 5 .06).Stem Cell Mobilization, Collection, and
Engraftment
In all patients, the stem cell mobilization regi-
men included granulocyte colony-stimulating factor
10-16 mg/kg/day for 3-4 days. The median number
of stem cells collected was 6.8  106 CD341
cells/kg (range, 0.2-31.4  106 CD341 cells/kg) in
all patients with BM amyloid deposition (both vas-
cular and interstitial) and 7.2  106 CD341 cells/
kg (range, 0.6-24.1  106 CD341 cells/kg) in pa-
tients with interstitial amyloid (Table 2). In patients
without BM amyloid deposition, median stem cell
collection was 6.9  106 CD341 cells/kg (range,
0.28-20.4  106 CD341 cells/kg). This value was
not statistically significantly different from that in
either all patients with BM amyloid deposits or
those with only interstitial amyloid deposits(P 5 .79). A mean of 2 collections was required in
all groups.
In the total cohort, 8 patients died before neutro-
phil engraftment, and 10 additional patients died be-
fore platelet engraftment. These patients were
excluded from engraftment analyses. The median
time to neutrophil engraftment was 10 days (range,
5-16 days) in all patients with BM amyloid deposition
and those with interstitial BM amyloid deposition
only, and 10 days (range, 8-17 days) in patients without
BM amyloid deposition. There were no significant dif-
ferences among these groups (P 5 .691 and .213,
respectively).
The median time to platelet engraftment was
13 days (range, 7-93 days) in patients with BM amyloid
deposition, 13 days (range, 7-32 days) in patients with
interstitial BM amyloid deposition, and 12 days (range,
8-46 days) in patients without BM amyloid deposition.
There were no significant differences among these
groups (P 5 .177 and .79, respectively).
Thirty-eight patients (11%) experienced mobiliza-
tion failure, defined as collection of\2.5 106CD341
cells/kg.However, thesepatients did proceed toHDM-
SCT after undergoing BM harvest. The proportion of
failures was not significantly different between all
patients with BM amyloid deposition and the subgroup
with extensive amyloid deposition (P 5 .15 and 1.0,
respectively). No significant differences in BM harvest
were observed among these groups (P 5 .23 and 1.0,
respectively). Notably, 22 (58%) of these patients
received pretreatment, the majority (95%) with oral
melphalan.
BM amyloid deposition was relatively common in
our series of 361 patients with AL amyloidosis who
underwent HDM-SCT, occurring in 65% of pa-
tients. Theoretically, given the potential extensive na-
ture of amyloid BM deposition, this could impede
stem cell collection and engraftment after HDM-
SCT. Nonetheless, neither vascular nor more exten-
sive interstitial BM amyloid deposition had any neg-
ative impact on stem cell mobilization, stem cell
collection, or neutrophil and platelet engraftment ki-
netics. Indeed, our engraftment data are similar to
previously published posttransplantation stem cell
engraftment data in these patients [8], but the num-
bers here are much larger and encompass more years
of study.
1938 Biol Blood Marrow Transplant 18:1935-1944, 2012A. J. Cowan et al.In keeping with previous findings from our institu-
tion, kappa clonality was more common in patients
with BM amyloid deposition than in those without
this deposition [9]. The association of amyloid BM
deposition and greater renal and multiorgan involve-
ment merits further investigation.ACKNOWLEDGMENTS
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